Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
MDRX Stock Forecast 2025-2026
$4.85
Current Price
$522.72M
Market Cap
Buy 1
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to MDRX Price Targets
+64.9%
To High Target of $8.00
+3.1%
To Median Target of $5.00
-7.2%
To Low Target of $4.50
MDRX Price Momentum
-3.0%
1 Week Change
-3.0%
1 Month Change
-55.7%
1 Year Change
-50.3%
Year-to-Date Change
-55.9%
From 52W High of $11.00
+61.7%
From 52W Low of $3.00
📊 TOP ANALYST CALLS
Did MDRX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Allscripts is one of their latest high-conviction picks.
Latest MDRX Stock Price Targets & Analyst Predictions
Based on our analysis of 18 Wall Street analysts, MDRX has a neutral consensus with a median price target of $5.00 (ranging from $4.50 to $8.00). The overall analyst rating is N/A (N/A/10). Currently trading at $4.85, the median forecast implies a 3.1% upside. This outlook is supported by 1 Buy, 2 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MDRX Analyst Ratings
1
Buy
2
Hold
0
Sell
MDRX Price Target Range
Low
$4.50
Average
$5.00
High
$8.00
Current: $4.85
Latest MDRX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MDRX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jan 31, 2025 | Stephens & Co. | Jeff Garro | Equal-Weight | Maintains | $13.00 |
| May 28, 2024 | TD Cowen | Charles Rhyee | Buy | Maintains | $15.00 |
| Mar 19, 2024 | Deutsche Bank | George Hill | Hold | Downgrade | $10.00 |
| Jan 19, 2024 | RBC Capital | Sean Dodge | Outperform | Maintains | $11.00 |
| Jan 3, 2024 | Barclays | Stephanie Davis | Equal-Weight | Initiates | $11.00 |
| Nov 14, 2023 | Stephens & Co. | Jeff Garro | Equal-Weight | Reiterates | $13.00 |
| Oct 10, 2023 | Stephens & Co. | Jeff Garro | Equal-Weight | Reiterates | $13.00 |
| Jul 6, 2023 | Argus Research | Jasper Hellweg | Hold | Downgrade | $N/A |
| Apr 12, 2023 | Stephens & Co. | Jeff Garro | Equal-Weight | Initiates | $13.00 |
| Feb 1, 2023 | Piper Sandler | Jessica Tassan | Neutral | Downgrade | $18.50 |
| Dec 7, 2022 | Argus Research | Jasper Hellweg | Buy | Upgrade | $26.00 |
| Nov 18, 2022 | JP Morgan | Anne Samuel | Underweight | Maintains | $20.00 |
| Nov 9, 2022 | Goldman Sachs | Cindy Motz | Buy | Upgrade | $23.00 |
| Sep 16, 2022 | Keybanc | Scott Schoenhaus | Sector Weight | Initiates | $N/A |
| Jul 12, 2022 | Goldman Sachs | Cindy Motz | Neutral | Initiates | $21.00 |
| Jun 10, 2022 | Piper Sandler | Jeff Garro | Neutral | Maintains | $17.00 |
| May 6, 2022 | Piper Sandler | Jeff Garro | Neutral | Maintains | $19.00 |
| Mar 18, 2022 | Piper Sandler | Jeff Garro | Neutral | Maintains | $22.00 |
| Mar 4, 2022 | Deutsche Bank | George Hill | Buy | Upgrade | $26.00 |
| Mar 3, 2022 | SVB Leerink | Stephanie Davis | Outperform | Maintains | $24.00 |
Veradigm Inc. (MDRX) Competitors
The following stocks are similar to Allscripts based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Veradigm Inc. (MDRX) Financial Data
Veradigm Inc. has a market capitalization of $522.72M with a P/E ratio of 11.0x. The company generates $588.02M in trailing twelve-month revenue with a -14.7% profit margin.
Revenue growth is +5.0% quarter-over-quarter, while maintaining an operating margin of +16.6% and return on equity of -1.7%.
Valuation Metrics
Market Cap
$522.72M
Enterprise Value
$245.88M
P/E Ratio
11.0x
PEG Ratio
5.6x
Price/Sales
0.9x
Growth & Margins
Revenue Growth (YoY)
+5.0%
Gross Margin
+54.9%
Operating Margin
+16.6%
Net Margin
-14.7%
EPS Growth
-10.2%
Financial Health
Cash/Price Ratio
+93.8%
Current Ratio
3.0x
Debt/Equity
18.6x
ROE
-1.7%
ROA
-0.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Veradigm Inc. (MDRX) Business Model
About Veradigm Inc.
What They Do
Healthcare technology solutions connecting providers and payers.
Business Model
Veradigm Inc. generates revenue by offering electronic health records (EHR), practice management software, and analytics tools to healthcare providers, payers, and life science organizations. The company's services aim to enhance clinical, financial, and operational outcomes, supporting a vast network of over 180,000 physicians and 2,700 hospitals.
Additional Information
Rebranded from Allscripts in 2023, Veradigm focuses on scalable, AI-enhanced solutions and has a significant healthcare data network for actionable insights. Despite facing regulatory challenges, including a Nasdaq suspension for delayed filings, the company remains a key player in healthcare IT, emphasizing interoperability and data standards.
Company Information
Sector
Healthcare
Industry
Health Information Services
Employees
2,450
CEO
Mr. Thomas J. Langan
Country
United States
IPO Year
1999
Website
veradigm.comVeradigm Inc. (MDRX) Latest News & Analysis
Latest News
Quick Summary
Veradigm (OTCMKTS: MDRX) announced enhancements to its AI-driven Ambient Scribe solution for EHR customers, aiming to improve clinical documentation and patient care.
Why It Matters
Veradigm's AI enhancements signal growth in healthcare technology, potentially increasing market share and revenue, which can positively impact stock performance for investors.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Veradigm (OTCMKTS: MDRX) has partnered with Sentara Health Plans to implement its Payer Insights software, enhancing care gap alerts in EHR systems for over one million members.
Why It Matters
Veradigm's agreement with Sentara Health Plans enhances its market position by integrating advanced software into EHR systems, potentially increasing revenue and user adoption in the healthcare sector.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Veradigm (OTCMKTS: MDRX) appointed Tehsin Syed as Chief Product and Technology Officer. Syed has over 20 years of experience and previously led AWS Health AI, driving growth and new product development.
Why It Matters
Tehsin Syed's appointment as Chief Product and Technology Officer signals potential innovation and growth at Veradigm, which could enhance its market position and attract investor interest.
Source: Business Wire
Market Sentiment:
Neutral
Veradigm Inc. - Special Call
2 months ago
Quick Summary
Veradigm Inc. held an Investor Update Conference Call featuring executives, including CEO Donald Trigg and Interim CFO Leland Westerfield. The call was recorded for future reference.
Why It Matters
Veradigm's investor update indicates potential strategic shifts or financial insights, impacting stock performance and investor sentiment. Monitoring such calls can provide critical market intelligence.
Source: Seeking Alpha
Market Sentiment:
Neutral
Veradigm Provides 2025 Business Update
2 months ago
Quick Summary
Veradigm (OTCMKTS: MDRX) reported estimated Q2 2025 financial performance, financing updates, and reaffirmed its 2025 outlook. Donald Trigg has been appointed CEO as of September 2.
Why It Matters
Veradigm's financial estimates and leadership changes signal potential growth and stability, influencing investor confidence and stock performance in the healthcare tech sector.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Edelson Lechtzin LLP is investigating data privacy claims related to an incident at Veradigm LLC, potentially impacting the company's operations.
Why It Matters
Data privacy claims against Veradigm LLC could lead to legal liabilities and reputational damage, potentially impacting stock performance and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About MDRX Stock
What is Veradigm Inc.'s (MDRX) stock forecast for 2026?
Based on our analysis of 18 Wall Street analysts, Veradigm Inc. (MDRX) has a median price target of $5.00. The highest price target is $8.00 and the lowest is $4.50.
Is MDRX stock a good investment in 2026?
According to current analyst ratings, MDRX has 1 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $4.85. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for MDRX stock?
Wall Street analysts predict MDRX stock could reach $5.00 in the next 12 months. This represents a 3.1% increase from the current price of $4.85. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Veradigm Inc.'s business model?
Veradigm Inc. generates revenue by offering electronic health records (EHR), practice management software, and analytics tools to healthcare providers, payers, and life science organizations. The company's services aim to enhance clinical, financial, and operational outcomes, supporting a vast network of over 180,000 physicians and 2,700 hospitals.
What is the highest forecasted price for MDRX Veradigm Inc.?
Price targets from Wall Street analysts for MDRX are not currently available. The stock is trading at $4.85.
What is the lowest forecasted price for MDRX Veradigm Inc.?
The lowest price target for MDRX is $4.50 from at , which represents a -7.2% decrease from the current price of $4.85.
What is the overall MDRX consensus from analysts for Veradigm Inc.?
The overall analyst consensus for MDRX is neutral. Out of 18 Wall Street analysts, 1 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $5.00.
How accurate are MDRX stock price projections?
Stock price projections, including those for Veradigm Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 6, 2025 10:09 AM UTC